Company Overview and News

 
Brookfield Selling Assets to Build War Chest for Next Downturn - Bloomberg

2018-02-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Dear Millennials, How Do We Protect Our Principal?

2018-01-30 seekingalpha
A discussion of how to protect principal from the perspective of someone who has never had invested assets during a recession.
Upvote Downvote

1
Offshoot of Fallen Clean Energy Giant Takes It Slow - Bloomberg

2018-01-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

1
SUNE / SunEdison, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-08 fintel.io
SunEdison, Inc. (NYSE:SUNE) has 11 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 11,895,228 shares. Largest shareholders include Strategic Value Partners, LLC, Gofen & Glossberg Llc /il/, Firsthand Capital Management, Inc., Cohen Capital Management, Inc., Panagora Asset Management Inc, Regal Wealth Group, Inc.
Upvote Downvote

 
SUNE / SunEdison, Inc. / Strategic Value Partners, LLC - SC 13D (Activist Investment)

2018-01-08 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No.    )*     SunEdison, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) N/A (CUSIP Number) David B. Charnin Strategic Value Partners, LLC 100 West Putnam Avenue Greenwich, CT 06830 (203) 618-3500 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December
Upvote Downvote

1
SUNE / SunEdison, Inc. / Strategic Value Partners, LLC - SC 13D (Activist Investment)

2018-01-08 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No.    )*     SunEdison, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) N/A (CUSIP Number) David B. Charnin Strategic Value Partners, LLC 100 West Putnam Avenue Greenwich, CT 06830 (203) 618-3500 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December
Upvote Downvote

 
Brookfield to Buy Westinghouse's Global Nuclear Business - Bloomberg

2018-01-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

1
Hero Future emerges front-runner in race for Orange Renewable

2018-01-02 livemint
New Delhi: In what will rank among the top deals in India’s clean energy space, Munjal family-promoted Hero Future Energies Pvt. Ltd has emerged as the front-runner to acquire Orange Renewable from Singapore-based AT Capital Group.
Upvote Downvote

 
SUNE / SunEdison, Inc. FORM 15-12B FOR SUNEDISON, INC.

2017-12-31 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15   CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.  Commission File Number: 001-13828 SunEdison, Inc. (Exact name of registrant as specified in its charter)   Two CityPlace Drive, Suite 200 St.
Upvote Downvote

 
SUNE / SunEdison, Inc. POST EFFECTIVE AMENDMENT TO S-8

2017-12-18 sec.gov
As filed with the Securities and Exchange Commission on December 18, 2017 Registration No. 333-19159 Registration No. 333-43474 Registration No. 333-163318 Registration No. 333-166623 Registration No. 333-172396 Registration No. 333-183550 Registration No.  333-205346       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO.
Upvote Downvote

 
SUNE / SunEdison, Inc. POST EFFECTIVE AMENDMENT TO S-8

2017-12-18 sec.gov
As filed with the Securities and Exchange Commission on December 18, 2017 Registration No. 333-19159 Registration No. 333-43474 Registration No. 333-163318 Registration No. 333-166623 Registration No. 333-172396 Registration No. 333-183550 Registration No.  333-205346       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO.
Upvote Downvote

 
SUNE / SunEdison, Inc. POST EFFECTIVE AMENDMENT TO S-8

2017-12-18 sec.gov
As filed with the Securities and Exchange Commission on December 18, 2017 Registration No. 333-19159 Registration No. 333-43474 Registration No. 333-163318 Registration No. 333-166623 Registration No. 333-172396 Registration No. 333-183550 Registration No.  333-205346       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO.
Upvote Downvote

 
SUNE / SunEdison, Inc. POST EFFECTIVE AMENDMENT TO S-8

2017-12-18 sec.gov
As filed with the Securities and Exchange Commission on December 18, 2017 Registration No. 333-19159 Registration No. 333-43474 Registration No. 333-163318 Registration No. 333-166623 Registration No. 333-172396 Registration No. 333-183550 Registration No.  333-205346       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO.
Upvote Downvote

 
SUNE / SunEdison, Inc. POST EFFECTIVE AMENDMENT TO S-8

2017-12-18 sec.gov
As filed with the Securities and Exchange Commission on December 18, 2017 Registration No. 333-19159 Registration No. 333-43474 Registration No. 333-163318 Registration No. 333-166623 Registration No. 333-172396 Registration No. 333-183550 Registration No.  333-205346       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO.
Upvote Downvote

 
SUNE / SunEdison, Inc. POS AM FOR SUN EDISON INC.

2017-12-18 sec.gov
As filed with the Securities and Exchange Commission on December 18, 2017 Registration No. 333-191053 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933   SunEdison, Inc. (Exact name of registrant as specified in its charter)         Delaware   56-1505767 (State or other jurisdiction of incorporation or organization)   (IRS Employer Identification No.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 86732Y109